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AbstrACt
Introduction Anastomotic stricture formation is the most 
common postoperative complication after oesophageal 
atresia (OA) repair. The standard of care is endoscopic 
dilatation. A possible adjuvant treatment is intralesional 
steroid injection, which is thought to inhibit scar tissue 
formation and thereby to prevent stricture recurrence. We 
hypothesise that this intervention could prevent refractory 
strictures and reduce the total number of dilatations 
needed in these children.
Methods and analysis This is an international 
multicentre randomised controlled trial. Children with 
OA type C (n=110) will be randomised into intralesional 
steroid injection followed by balloon dilatation or dilatation 
only. Randomisation and intervention will take place 
when a third dilatation is performed. The indication for 
dilatation will be confirmed with an oesophagram. One 
radiologist—blinded for randomisation—will review 
all oesophagrams. The primary outcome parameter is 
the total number of dilatations needed with <28 days’ 
interval, which will be analysed with a linear- by- linear χ2 
association test. Secondary outcome parameters include 
the level of dysphagia, the luminal oesophageal diameter 
and stricture length (measured on the oesophagrams), the 
influence of comedication on stricture formation, systemic 
effects of intralesional steroids (cortisol levels, length and 
weight) and the cost- effectiveness. Patients will undergo a 
second oesophagram; length and weight will be measured 
repeatedly; a scalp hair sample will be collected; and three 
questionnaires will be administered. The follow- up period 
will be 6 months, with evaluation at 2–3 weeks, 3 and 6 
months after the intervention.
Ethics and dissemination Patients will be included after 
written parental informed consent. The risks and burden 
associated with this trial are minimal. The institutional 
review board of the Erasmus Medical Centre approved 
this protocol (MEC-2018–1586/NL65364.078.18). The 
results of the trial will be published in a peer- reviewed 
scientific journal and will be presented at international 
conferences.
trial registration numbers 2018-002863-24 and 
NTR7726/NL7484.
IntroduCtIon
Oesophageal atresia (OA) is a congenital 
malformation which can present with or 
without a tracheoesophageal fistula, with a 
European prevalence of 2.43 cases per 10 000 
births.1 2 With better treatments, survival rates 
have increased to over 90%.1 3 4 Still, anasto-
motic stricture formation remains the most 
frequent postoperative complication in up to 
60% of cases.5 Especially refractory strictures 
form a great burden for both patients and 
their parents.
The incidence of refractory strictures is 
poorly reported due to the variety in defi-
nitions used in literature. Regarded as a 
consensus among experts, the European 
Society for Paediatric Gastroenterology 
strengths and limitations of this study
 ► This is the first prospective study investigating the 
effectiveness of intralesional steroid injection com-
bined with endoscopic dilatation for the treatment of 
recurrent oesophageal strictures in children operat-
ed on for oesophageal atresia (OA).
 ► The determination of long- term cortisol levels over 
a period of 3 months will give objective information 
on possible systemic effects of intralesional steroid 
injection in children with OA.
 ► Besides the effectiveness and safety of intralesional 
steroid injection, cost- effectiveness of this treat-
ment will be evaluated.
 ► The rarity of the disease makes patient recruitment 
challenging.
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Hepatology and Nutrition (ESPGHAN) has set the 
following definition for a refractory oesophageal stricture: 
an anatomical restriction without endoscopic inflamma-
tion that results in dysphagia after a minimum of five dila-
tation procedures at maximally 4- week intervals.6 7
Recently, the Dutch Consortium for Esophageal Atresia 
(DCEA) conducted a retrospective multicentre study in 
the Netherlands to assess risk factors for stricture forma-
tion in children with OA. The study population consisted 
of 436 children born with OA between 1999 and 2013 
with an end- to- end oesophageal anastomosis. Thirty- two 
(7.3%) of them required ≥5 dilatations within an interval 
of 28 days.5
The initial treatment of an anastomotic stricture 
consists of endoscopic dilatation, either balloon dilata-
tion or semirigid dilatation.6 Consensus on the preferred 
technique has not yet been established. A refractory stric-
ture requires multiple dilatations under general anaes-
thesia, for which the child needs to be hospitalised. This 
adds significantly to the burden of the disease. It is there-
fore important to minimise the occurrence of refractory 
strictures and with that the need for dilatations.
In a recent ESPGHAN guideline, various adjuvant 
treatments are mentioned, for example, intralesional 
or systemic steroids, topical mitomycin C, oesophageal 
stents and surgical resection. Our trial will focus on intral-
esional steroid injections since we as well as the other 
centres involved in this trial have had successful results 
with this treatment in several patients.8
The literature on intralesional steroid injection in 
children with OA is scarce, but promising results have 
been described in both children and adults with all 
types of oesophageal strictures (table 1). Most studies 
are outdated case reports or series.9–14 Four relatively 
recent randomised controlled trials (RCTs) on this topic 
included only adults with underlying diagnoses other than 
OA, like caustic strictures after acid ingestion, peptic stric-
tures and anastomotic strictures after oesophagectomy 
with gastric tube reconstruction.15–18 Reported beneficial 
effects were reduction of dilatation procedures,16 longer 
intervals between dilatation procedures,17 improvement 
of luminal diameter15 and relief of dysphagia.18
In children, only retrospective studies have been 
performed, which mostly included caustic strictures.19 20 
Divarci et al analysed data of 32 children with corrosive 
strictures with a mean age of 3.6 years (±2.5 years); after 
the intervention, the number of dilatations had signifi-
cantly decreased and the intervals between dilatations 
had extended.19 Cakmak et al included 38 children with 
either OA or corrosive strictures with a median age of 1.5 
years (range 0–14 years)20 but did not find a significant 
difference in treatment effectiveness. None of the above- 
mentioned studies reported any systemic effects of the 
local intralesional steroid injections.
All studies used triamcinolone acetonide (TAC). The 
exact mechanism by which TAC enhances the efficacy 
of dilatation is unclear. It has been proven very effective 
in the treatment of hypertrophic scars of the skin and 
keloid. A recurring anastomotic stricture can be seen as 
a hypertrophic lesion. The injected TAC inhibits collagen 
formation, enhances collagen breakdown, decreases 
fibrotic healing that occurs after dilatation and prevents 
cross- linking of collagen that causes contractions in scar 
tissue.21 22
The recurrent dilatations and readmissions impose 
a substantial burden on the healthcare system. To date, 
there is no evidence on the cost- effectiveness of intrale-
sional steroid injections. However, in the current era of 
evidence- based and cost- effective medicine, proof of cost- 
effectiveness is highly relevant.
The primary objective was to evaluate whether intrale-
sional steroid injections combined with endoscopic dila-
tation can prevent refractory strictures in children with 
OA and recurrent oesophageal stenosis, and thus can 
minimise the number of dilatations needed with a 28 
days’ interval between the dilatations.
The secondary objectives were
 ► To compare the level of dysphagia and the child’s 
eating behaviour between the two groups.
 ► To compare the effect of intralesional steroid injec-
tions on the luminal diameter and the stricture length 
between the two groups.
 ► To evaluate a possible influence of comedication (eg, 
antacids) on stricture formation.
 ► To analyse the possible systemic effects of a one- time 
intralesional steroid injection.
 ► To analyse the cost- effectiveness of the use of intral-
esional steroid injections to prevent refractory 
strictures.
MEthods And AnAlysIs
The STEPS- EA trial is an international, multicentre, 
single- blinded RCT with a 1:1 randomisation to injection 
with 10 mg/mL TAC (Kenacort- A 10) prior to balloon 
dilatation and balloon dilatation without any injection. 
The participating centres are tertiary (academic) hospi-
tals that collaborate within the European Reference 
Network on Inherited and Congenital Abnormalities 
(ERNICA,  ern- ernica. eu) and that routinely provide care 
for children with OA.
Patient and public involvement
Parents of patients were involved in the end stage of 
the design of the trial. We presented our plans for the 
trial to a DCEA meeting in which also representatives 
of the patients’ association Vereniging voor Ouderen 
en Kinderen met een Slokdarmafsluiting (VOKS) took 
part. They were invited to comment on the study design, 
intervention or time required to participate in this trial. 
Consensus was reached on the final design during this 
meeting. The patients’ association will not be involved in 
the recruitment and conduct of the trial. We will involve 
them in dissemination, however, by presenting the trial 
results at a members’ day or in their monthly newsletter. 
As the VOKS is a member of the European Federation 
of Esophageal Atresia and Tracheoesophageal fistula 
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Table 1 Summary of literature on clinical findings on intralesional steroid injections for oesophageal strictures, including 
retrospective cohort studies in children <12 years (range 0–14 years)
Author (year) Type of study Characteristics Main outcomes
Camargo et al 
(2003)15
Double- blind RCT 14 adult patients, corrosive 
strictures
 ► No significant difference in dilatation frequency 
and dysphagia.
 ► Significant improvement in obtained diameter 
(p<0.05).
 ► No adverse events reported.
Ramage et al 
(2005)16
Double- blind RCT 30 adult patients, peptic 
strictures
 ► Less patients required repeat dilatation in the 
steroid group (13% vs 60%, p=0.0209).
 ► Shorter time to repeat dilatation in the control 
group (p=0.01).
 ► No adverse events reported.
Hirdes et al (2013)17 Double- blind RCT 60 adult patients, anastomotic 
strictures after oesophagectomy 
with gastric tube reconstruction
 ► No significant decrease in frequency of repeat 
dilatation or prolongation of dysphagia- free 
period.
 ► Four patients developed Candida oesophagitis.
Pereira- Lima et al 
(2015)18
Double- blind RCT 19 adult patients, anastomotic 
strictures after oesophagectomy 
with gastric tube reconstruction
 ► Significant improvement on dysphagia at 1 and 6 
months (p=0.021 and p=0.009).
 ► No perforation or haemorrhage of oesophageal 
candidiasis, no other adverse events reported.
Kochhar and 
Makharia (2002)35
Prospective 71 patients (13–78 year), all 
kinds of strictures
 ► Periodic dilatation index decreased significantly 
after injection (p<0.001).
 ► No adverse events reported.
Nijhawan et al 
(2016)36
Prospective 11 adult patients, corrosive 
strictures
 ► Significant improvement of maximum dilatation 
(p<0.001) and number of dilatations per month 
(p<0.001).
 ► No adverse events reported.
Divarci et al (2016)19 Retrospective 32 children (mean age 
3.6 years), corrosive strictures
 ► Mean number of dilatation sessions was 
decreased (p=0.003).
 ► Mean frequency of dilatations in weeks extended 
(p<0.001).
 ► Only a positive effect in short- segment strictures 
(<3 cm, 92% of patients dysphagia- free).
 ► No serious adverse events reported, one transient 
cushingoid phenotype but no real adrenal 
suppression.
Cakmak et al 
(2016)20
Retrospective 38 children (median age 
1.5 years), OA (n=19) and 
corrosive strictures (n=19)
 ► No significant difference in treatment 
effectiveness between steroid injection and others 
(p>0.05).
 ► Intralesional steroid injections performed only in 
patients with long (>5 cm) and corrosive strictures 
and ≥5 dilatations.
 ► Four patients with oesophageal perforation at 
other dilatation sessions than the intralesional 
steroid injection.
OA, oesophageal atresia; RCT, randomised controlled trial.
Support Groups E.V., patients and parents throughout 
Europe will be informed about the results.
Participants
OA can be a very heterogeneous disease. About 90% of 
the children with OA has type C.5 23 In order to make 
the two treatment groups as equal as possible, only 
children with OA type C who underwent surgery with 
primary anastomosis within the first days of life and 
who developed a recurrent oesophageal stricture will be 
eligible. Children will be included if they are ≥3 months 
old at the time of the intervention and in need of a 
third dilatation. Written parental informed consent will 
be obtained by the local principal investigator (PI) or 
another member of the local research team. Exclusion 
criteria are lack of parental consent or an impossibility—
known from previous dilatations—to use an endoscope 
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Table 2 Assumed relative frequencies of the number of dilatations in the control and steroid groups
Number of dilatations within 28 
days’ interval
Observed number of 
patients (n=407)5
Relative frequencies, 
control group
Assumed relative frequencies, 
steroid group
3 dilatations 4 0.075 0.142
4 dilatations 7 0.132 0.302
5 dilatations 9 0.170 0.170
6 dilatations 7 0.132 0.160
7–10 dilatations 16 0.302 0.132
>10 dilatations 10 0.189 0.094
Total (all numbers of dilatations 
combined)
53 1.000 1.000
with a large enough diameter working channel to pass 
the endoscopic injector.
sample size calculation
The power calculation is based on a linear- by- linear χ2 
association test comparing the total number of dilata-
tions required within the study period (all strictures) and 
within a 28- day interval (refractory strictures) between 
the two treatment groups. The total number of dilatations 
will be categorised into the categories 3, 4, 5, 6, 7–10 and 
>10 dilatations, and a separate category for patients who 
are not dysphagia- free at the end of the follow- up period.
For this power calculation, we used data of the original 
dataset of our retrospective study in the Netherlands.5 We 
selected patients from this dataset who underwent at least 
three dilatations with a 28- day interval (n=53). The retro-
spective study’s observed numbers of patients and the 
relative frequencies for each category are listed in table 2. 
We assumed that the use of intralesional steroid injections 
combined with endoscopic dilatation will reduce the total 
number of dilatations by 50%. Note that this 50% reduc-
tion applies only to dilatations after the third dilatation, 
and therefore no change in the number of dilatations 
is assumed for the first three dilatations. This assump-
tion leads to a different distribution for the number of 
dilatations within the categories, which is shown as the 
assumed relative frequencies for the steroid group in the 
final column of table 2. The details of the calculation are 
provided in online supplementary file 1.
In a simulation model, the required sample size to 
obtain a power of 80% (with a two- sided significance level 
of 0.05) was calculated as 52 patients per group, thus 104 
in total. To account for the effects of dropout and missing 
data, we aimed to include a total of 110 patients.
recruitment
Patients will be recruited from hospitals in various Euro-
pean countries. Up until now, hospitals in Denmark, UK, 
Finland, France, Italy and Sweden have agreed to partici-
pate. During the inclusion period, it will remain possible 
for other centres to join. To achieve adequate participant 
enrolment, we have minimalised the exclusion criteria. 
Collaboration within ERNICA should make patient 
accrual achievable despite the rarity of the disease.
randomisation, blinding and treatment allocation
Randomisation will be conducted via ALEA (FormsVision 
B.V./ALEA Clinica B.V.), a validated software program. 
To achieve equal distribution of the intervention among 
the participating sites, block randomisation stratified per 
centre will be carried out. The software was prepared by 
an independent statistician who is not otherwise involved 
in the study. After inclusion, the local PI will enter the 
patient in ALEA and will thereupon receive an email 
stating the allocated treatment.
Randomisation will be blinded for the radiologist who 
will review all oesophagrams. The control group will not 
receive sham treatment. The steroid that will be used, 
Kenacort- A 10 (see further), is a white suspension, which 
complicates creating a placebo. Adding excipients to 
normal saline is undesirable, considering the unknown 
effect on the healing process of the stricture. Moreover, it 
is deemed undesirable to inject an infant with a fluid with 
an unknown effect.
Investigational product
The intervention will be a one- time endoscopic injec-
tion of 0.25 mL Kenacort- A 10 (Bristol- Myers Squibb BV, 
Utrecht, the Netherlands) in each quadrant of the stric-
ture prior to the third endoscopic dilatation. Thus, in 
total, 1 mL (10 mg/mL TAC, equals 12.5 mg prednisone) 
will be injected. During the study period, none of the 
patients will receive a second injection.
Kenacort- A 10 will be prepared, labelled and distrib-
uted by the trial pharmacy of the coordinating hospital. It 
will be delivered to the local pharmacies by courier, and 
the local pharmacy will deliver it to the operation room 
when needed. After the trial, a specific procedure for 
destruction of the remaining drugs is not needed; they 
can be disposed of locally.
Patient timeline
Figure 1 presents a flowchart for this study and the study 
procedures. The treating physician will decide on a third 
dilatation on the basis of the clinical signs of dysphagia 
and the findings on the oesophagram (thoracic X- ray 
with contrast, anterior–posterior and lateral). Clinical 
signs of dysphagia are defined as the inability to be fed age 
appropriately. Findings on the oesophagram indicating 
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Figure 1 Flowchart of the study design. Bold with underline indicates study procedures; the rest is standard of care. AP, 
anterior–posterior; iPCQ, iMTA Productivity Cost Questionnaire; MFS, Montreal Feeding Scale; OA, oesophageal atresia.
a stricture are defined as a significant narrowing of the 
lumen, seen as a waist in the contrast on the X- ray. The 
treating physician can be a paediatric surgeon or a paedi-
atric gastroenterologist, depending on the local agree-
ments in the different countries. After parental informed 
consent, the patient will be included and randomised to 
one of the study arms.
Prior to the balloon dilatation, an endoscopic needle 
(DVI-23- MH varices injector or equivalent) is prefilled 
with 1 mL Kenacort- A 10 and passed through the endo-
scope. Under direct vision, 0.25 mL will be injected in 
each of the four quadrants of the circular stricture. After 
the injection needle has been retracted from the working 
channel and good visualisation has been re- established, 
balloon dilatation will be performed up to the desired 
diameter. The balloon will remain insufflated for 1 min.
During a follow- up period of 6 months, patients will not 
receive any (additional) steroid injections, only balloon 
dilatations if needed. Meaning, patients in the steroid 
group will only receive one injection, and patients in the 
control group will receive no injections at all. After the 
study period has ended, treatment is again free of choice.
Two to 3 weeks after the dilatation procedure, a second 
oesophagram will be made in children in both study 
groups. All oesophagrams will be reviewed by one special-
ised paediatric radiologist of the coordinating hospital, 
who will determine the oesophageal diameter and 
stricture length. Earlier studies have proven that these 
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measurements can be obtained from an oesophagram.24 
The parents will be informed about the results and the 
normal standard of care will be continued.
Each patient will be followed up for 6 months after the 
third dilatation, with recording of possible side effects, 
complications and additional dilatations. Length and 
weight will be measured at 2–3 weeks, 3 and 6 months 
after the third dilatation. In the context of the cost- 
effectiveness analysis, the parents will be asked to fill 
out a modified version of the iMTA Productivity Cost 
Questionnaire (iPCQ)25 at 3 months after the third 
dilatation.
At evaluation at 6 months, we will collect a scalp hair 
sample from the child to determine long- term cortisone 
and cortisol levels.26 27 The hair locks will be stored for 
final batch analysis. Lastly, the parents will be asked to fill 
out the Montreal Feeding Scale (MFS)28–30 and again the 
iPCQ. After this, the study period will end.
outcome parameters
The primary outcome parameter is the total number of 
dilatations required per patient with a 28- day interval 
between the dilatations during the study period of 
6 months, which is defined as the period from the day of 
the third dilatation until 6 months later.
The secondary outcome parameters are as follows:
1. Total number of dilatations within the study period, 
regardless of the interval.
2. Interval (in weeks) between the start of the study and 
the last dilatation procedure within the study period.
3. Scores on the MFS.
4. The change in maximal luminal diameter after the 
third dilatation relative to the diameter before the 
third dilatation: relative change in luminal diame-
ter=(maximal diameter after–maximal diameter be-
fore)/maximal diameter before. The diameter will be 
measured at the narrowest point of the oesophagus.
5. The change in the length of the oesophageal stric-
ture after the third dilatation relative to the length 
before the third dilatation: relative change in stric-
ture length=(stricture length after–stricture length 
before)/stricture length before. The length will be 
measured between the two points where the oesoph-
ageal diameter starts narrowing.
6. The use of comedication (eg, antacids) during the 
study period.
7. The mean hair cortisol levels in the first 3 months af-
ter the third dilatation. Cortisol levels will be adjusted 
for age and sex.
8. Delta length SD scores (SDSs) and delta weight SDS 
between the third dilatation (intervention) and 3 and 
6 months after the third dilatation.
9. Total costs of the treatment, including medical and 
non- medical costs.
10. Incremental costs per refractory stricture prevented 
and incremental costs per additional dysphagia- free 
patient.
data collection
All participating centres are familiar with the procedure 
of injecting Kenacort- A 10 in the lesion via an injection 
needle through the endoscope. However, to guarantee 
equality of the intervention, the relevant practitioners in 
all centres will be trained by the PI of the trial. Radiolog-
ical interobserver variability will be avoided by having all 
oesophagrams reviewed by one radiologist.
The internationally validated MFS28–30 will be used to 
measure dysphagia. The MFS has often been used in 
previous research in children with OA. The scalp hair 
sample will be taken from the posterior vertex; cortisol 
levels will be determined with the liquid chromatog-
raphy–tandem mass spectrometry method for quantifica-
tion of steroids.26
The cost- effectiveness analysis will follow established 
methods for economic evaluations and costing studies in 
healthcare.31 32 Both medical and non- medical costs will 
be collected. Medical costs will include costs of surgeries 
(dilatations), steroid injections, hospital days (on the 
ward or the intensive care unit), medication (such as anal-
gesics) and diagnostic radiography. Costs of healthcare 
provided by others than the participating centres (such as 
other hospitals or general practitioners) will be ignored in 
this study, as these are unlikely to be affected by the inter-
vention. Non- medical costs will include costs of special 
diets, costs related to hospital visits and productivity losses 
related to both paid and unpaid works. The non- medical 
costs will be measured using the iPCQ,25 supplemented 
with additional questions on costs of special diets and 
costs related to the child’s hospitalisation. The original 
iPCQ questions are validated in English. The complete 
questionnaire including the additional questions will be 
translated to the languages required for this trial using 
the forward–backward translation method, as will the 
MFS for the languages it has not been validated for.
statistical analysis
Since a standardised treatment protocol will be adopted 
in all centres, statistical adjustment for centre effects is 
considered unnecessary.
The primary outcome parameter will be analysed with 
a linear- by- linear χ2 association test. The total number of 
dilatations required with a 28- day interval (ie, refractory 
strictures) within the study period of 6 months per patient 
will be categorised and compared between treatment 
groups. In case of death during the follow- up period, 
the outcome will be set to the highest (ie, most severe) 
category. In case of drop- out during the follow- up period 
due to other causes (eg, emigration and withdrawal), the 
subject will be excluded from the study.
The analyses for the secondary study parameters are as 
follows:
1. The total number of dilatations required within the 
study period (regardless of the interval, ie, all stric-
tures) will be categorised and compared between treat-
ment groups with a linear- by- linear χ2 association test.
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2. The interval (in weeks) until the patient is dysphagia- 
free will be compared between groups with the log- 
rank test and with Cox proportional hazards regres-
sion, with adjustment for treatment group and factors 
such as age, sex, diagnostic information and described 
risk factors for stricture formation like anastomotic 
leaking and thoracoscopic repair.5 Patients who do not 
become dysphagia- free during follow- up are treated as 
censored at the end of the follow- up period.
3. The scores on the MFS (reflecting the level of dyspha-
gia and the eating behaviour) will be compared be-
tween study groups with a Mann- Whitney test.
4. The relative change in the oesophageal diameter and 
that in the length of the oesophageal stricture will be 
compared between study groups with an analysis of co-
variance model. The dependent variables in this mod-
el will be the log- transformed oesophageal diameter 
and length after the third dilatation, and the indepen-
dent variables will be the treatment group and the log- 
transformed oesophageal diameter and length before 
third dilatation.
5. The effect of comedication on the primary study out-
come will be assessed using a stratified Mann- Whitney 
test with stratification for the treatment group.
6. The mean cortisol level over the first 3 months after 
the third dilatation will be compared between study 
groups with a linear regression model with adjustment 
for age and sex.
No missing data are expected for the independent 
variables in the analysis of covariance models and the 
Cox proportional hazards regression models. In case of 
missing data for any of the outcomes, a complete case 
analysis (ie, exclusion of the subjects who dropped out 
during the follow- up period) will be performed for the 
corresponding outcome.
Cost-effectiveness analysis
All medical and non- medical costs will be summated for 
each individual patient. Regarding the patient outcomes, 
the number of refractory strictures prevented and the 
number of dysphagia- free patients will be considered. 
Incremental cost- effectiveness ratios will be calcu-
lated, expressed as incremental costs per refractory 
stricture prevented and incremental costs per addi-
tional dysphagia- free patient. Analysis of uncertainty 
will be illustrated through cost- effectiveness planes (via 
bootstrapping).
As this RCT is done in an international setting, it must 
be recognised that the results may differ between coun-
tries because healthcare systems, treatment patterns and 
prices may vary. Therefore, country- level information will 
be collected. Data (especially resource quantities and 
cost prices) will be collected in all countries, and results 
will also be reported for each country separately. Next, 
a pooled summary calculation of the intervention’s cost- 
effectiveness will be made, converting all costs into a 
common currency base (ie, euros).
Adverse events and auditing
Adverse events will be handled according to the guidelines 
of the institutional review board (IRB) of the Erasmus 
Medical Centre. All adverse events will be registered 
during the study. Serious adverse events will be reported 
to the sponsor immediately and registered appropriately 
within 24 hours.
All participating sites will be audited once a year with 
monitoring of patient recruitment, source data verifica-
tion, drug accountability and sample storage. The auditor 
will be independent and not involved in the study.
benefits and risk assessment
The risks and burden associated with this study are 
minimal. Potential complications of oesophageal steroid 
injections include adrenal suppression, perforation, 
intramural infection, Candida infection, mediastinitis 
and pleural effusion.33 However, in previous studies, no 
adverse events have been reported in relation to the 
steroid injections (see table 1). Additionally, Kenacort- A 
10 is a slow- release medicine and therefore a gradual 
exposure. This implies that the likelihood of acute expo-
sure to a high dose of steroids will be minimal.
The burden of filling out the questionnaires and taking 
a hair sample are negligible. Filling out the MFS and the 
iPCQ will take maximally 30 min. All participants will 
undergo one extra oesophagram after the third dilatation 
procedure. The potential reduction in the number of 
anaesthetic procedures needed for dilatations outweighs 
the burden and the radiation exposure of this oesopha-
gram. Potential benefits of intralesional steroid injections 
are fewer dilatation procedures needed, with concom-
itant fewer anaesthetic procedures and hospital admis-
sions and less risk of perforation.
data management
All data will be handled confidentially and anonymously 
using OpenClinica V.3.12.2 (OpenClinica LLC, USA) for 
data collection. The questionnaires will be conducted 
through an online survey using LimeSurvey (LimeSurvey 
GmbH, Germany) and GemsTracker (Erasmus MC, 
Rotterdam, the Netherlands). All patient data will be 
coded using a subject identification code list. The local 
PI safeguards the key to the code; the sponsor will have 
access to these codes. The local PI will only have access to 
the data of patients of their own centre; the sponsor will 
have access to the final trial dataset. All has been stated in 
a clinical trial site agreement signed by all participating 
sites.
EthICs And dIssEMInAtIon
This study protocol was approved by the IRB of the Erasmus 
Medical Centre (MEC-2018–1586/NL65364.078.18). In 
case of any modifications of the protocol, a formal amend-
ment will be submitted to the IRB. Approved changes 
will be communicated to all relevant parties according 
to the rules of the IRB. The protocol has currently 
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been submitted for local ethical approval in Amsterdam 
(the Netherlands), Odense (Denmark), Copenhagen 
(Denmark), Stockholm (Sweden), Rome (Italy) and 
Padua (Italy). Nijmegen (the Netherlands) and Helsinki 
(Finland) have already obtained local ethical approval 
and joined the study. To guarantee the respect of ethical 
rules and standard of care in all participating centres, 
the protocol was reviewed by the two chairs of the work 
package on OA within ERNICA. The informed consent 
and assent process of this trial is in line with the Good 
Clinical Practice guideline.34
Furthermore, we involved external experts in the form 
of a data safety monitoring board (DSMB). These experts 
are a paediatric surgeon, a pharmacologist and a statis-
tician. All experts are independent of the sponsor and 
therefore competing interests will be avoided. The DSMB 
will monitor the safety of the study subjects and data. 
The board will meet at least three times: within 1 year 
of recruitment commencing, at the time of the planned 
interim analyses at 50% (n=55) of enrolment and at the 
conclusion of the trial.
The results of this trial will be published in an inter-
national peer- reviewed scientific journal, within 1 year 
after the end of the follow- up period of the last included 
patient. In addition, we aimed to present the results at 
several international conferences to inform healthcare 
professionals worldwide.
trIAl stAtus
The study has started in Rotterdam (the Netherlands) 
in February 2019 after ethical approval had been 
obtained. The first patient is included. Nijmegen (the 
Netherlands) has joined the study in October 2019 and 
Helsinki (Finland) in December 2019. At this moment, 
Amsterdam (the Netherlands), Odense (Denmark), 
Copenhagen (Denmark), Stockholm (Sweden), Rome 
(Italy) and Padua (Italy) are still waiting for local ethical 
approval. We expect to start the study in these sites the 
latest in 2020.
Considering the rarity of the disease, we expect to 
complete the inclusions and finish data collection for this 
study in 5 years.
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